RU2001122113A - The use of angiotensin II receptor antagonists for the treatment of acute myocardial infarction - Google Patents

The use of angiotensin II receptor antagonists for the treatment of acute myocardial infarction

Info

Publication number
RU2001122113A
RU2001122113A RU2001122113/14A RU2001122113A RU2001122113A RU 2001122113 A RU2001122113 A RU 2001122113A RU 2001122113/14 A RU2001122113/14 A RU 2001122113/14A RU 2001122113 A RU2001122113 A RU 2001122113A RU 2001122113 A RU2001122113 A RU 2001122113A
Authority
RU
Russia
Prior art keywords
acute
treatment
use according
pharmaceutically acceptable
angiotensin
Prior art date
Application number
RU2001122113/14A
Other languages
Russian (ru)
Other versions
RU2298405C2 (en
Inventor
Ессика М. МАНН
Паскаль ОДДУ
Эрик Мишель НЭАР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2001122113A publication Critical patent/RU2001122113A/en
Application granted granted Critical
Publication of RU2298405C2 publication Critical patent/RU2298405C2/en

Links

Claims (9)

1. Применение антагониста рецептора ангиотензина II или его фармацевтически приемлемой соли для приготовления лекарственного средства для лечения острого инфаркта миокарда (МИ) и для вторичной профилактики острого МИ.1. The use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute myocardial infarction (MI) and for the secondary prevention of acute MI. 2. Применение по п.1 антагониста рецептора ангиотензина II в сочетании с другим принятым действующим веществом для приготовления лекарственного средства для лечения острого МИ и для вторичной профилактики острого МИ.2. The use according to claim 1, an angiotensin II receptor antagonist in combination with another accepted active ingredient for the preparation of a medicament for the treatment of acute MI and for the secondary prevention of acute MI. 3. Применение по п.1 или 2 для приготовления лекарственного средства для лечения населения в целом, включая пациентов из группы высокого риска.3. The use according to claim 1 or 2 for the preparation of a medicinal product for the treatment of the general population, including patients from high-risk groups. 4. Применение по любому из пп.1-3, где антагонист AT1-рецептора выбирают из группы, включающей4. The use according to any one of claims 1 to 3, wherein the AT 1 receptor antagonist is selected from the group consisting of (а)(a)
Figure 00000001
Figure 00000001
 (б)(b)
Figure 00000002
Figure 00000002
 (в)(in)
Figure 00000003
Figure 00000003
 (г)(g)
Figure 00000004
Figure 00000004
 (д)(d)
Figure 00000005
Figure 00000005
 (е)(e)
Figure 00000006
Figure 00000006
 (ж)(g)
Figure 00000007
Figure 00000007
 (з)(h)
Figure 00000008
Figure 00000008
 (и)(and)
Figure 00000009
Figure 00000009
 (к)(to)
Figure 00000010
Figure 00000010
 и (л)and (l)
Figure 00000011
Figure 00000011
 или в каждом случае его фармацевтически приемлемую соль.or in each case a pharmaceutically acceptable salt thereof. 5. Применение по любому из пп.1-3, где антагонист рецептора ангиотензина II представляет собой валсартан формулы5. The use according to any one of claims 1 to 3, where the angiotensin II receptor antagonist is a valsartan of the formula
Figure 00000012
Figure 00000012
 или его фармацевтически приемлемую соль.or a pharmaceutically acceptable salt thereof. 6. Применение по любому из пп.2-5, где другое принятое действующее вещество для лечения острого МИ и для вторичной профилактики острого МИ выбирают из группы, включающей алацеприл, беназеприл, беназеприлат, каптоприл, церонаприл, цилазаприл, делаприл, эналаприл, эналаприлат, фосиноприл, имидаприл, лизиноприл, мовелтоприл, периндоприл, хинаприл, рамиприл, спираприл, темокаприл и трандолаприл.6. The use according to any one of claims 2-5, wherein the other active ingredient for the treatment of acute MI and for the secondary prophylaxis of acute MI is selected from the group consisting of alazepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, hinapril, ramipril, spirapril, temocapril and trandolapril. 7. Применение по п.6, где другое принятое действующее вещество представляет собой каптоприл.7. The use according to claim 6, where the other active ingredient is captopril. 8. Фармацевтическая композиция для лечения острого МИ и вторичной профилактики острого МИ, включающая блокатор АТ1-рецептора и другое принятое действующее вещество для лечения острой и хронической фаз инфаркта миокарда, выбранное из группы, включающей ингибитор АСЕ, бета-блокатор и аспирин или в каждом случае его фармацевтически приемлемую соль, в смеси с фармацевтически приемлемым носителем.8. A pharmaceutical composition for the treatment of acute MI and the secondary prevention of acute MI, comprising an AT 1 receptor blocker and another active ingredient for the treatment of acute and chronic phases of myocardial infarction selected from the group comprising an ACE inhibitor, beta-blocker and aspirin, or in each case, a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier. 9. Фармацевтическая композиция по п.8 для одновременного, раздельного или последовательного применения.9. The pharmaceutical composition of claim 8 for simultaneous, separate or sequential use.
RU2001122113/15A 1999-01-26 2000-01-24 Using angiotensin ii receptor antagonists in treatment of acute myocardial infarction RU2298405C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
EP99810061.4 1999-01-26
US46866499A 1999-12-21 1999-12-21
US09/468,664 1999-12-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2006135205/15A Division RU2345790C2 (en) 1999-01-26 2006-10-05 Application of angiotensin ii receptor antagonists for treatment of acute myocardial infarction

Publications (2)

Publication Number Publication Date
RU2001122113A true RU2001122113A (en) 2003-06-20
RU2298405C2 RU2298405C2 (en) 2007-05-10

Family

ID=26153740

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001122113/15A RU2298405C2 (en) 1999-01-26 2000-01-24 Using angiotensin ii receptor antagonists in treatment of acute myocardial infarction
RU2006135205/15A RU2345790C2 (en) 1999-01-26 2006-10-05 Application of angiotensin ii receptor antagonists for treatment of acute myocardial infarction

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2006135205/15A RU2345790C2 (en) 1999-01-26 2006-10-05 Application of angiotensin ii receptor antagonists for treatment of acute myocardial infarction

Country Status (25)

Country Link
EP (2) EP1714651A1 (en)
JP (1) JP2002535367A (en)
KR (1) KR100674053B1 (en)
CN (1) CN1337879A (en)
AT (1) ATE330599T1 (en)
AU (1) AU766453C (en)
BR (1) BR0007686A (en)
CA (1) CA2360691A1 (en)
CY (1) CY1105257T1 (en)
CZ (1) CZ20012682A3 (en)
DE (1) DE60028928T2 (en)
DK (1) DK1146872T3 (en)
ES (1) ES2265910T3 (en)
HK (1) HK1041808B (en)
HU (1) HUP0105199A3 (en)
ID (1) ID29818A (en)
IL (2) IL144216A0 (en)
NO (1) NO20013459L (en)
NZ (1) NZ513039A (en)
PL (1) PL197161B1 (en)
PT (1) PT1146872E (en)
RU (2) RU2298405C2 (en)
SI (1) SI1146872T1 (en)
SK (1) SK10522001A3 (en)
WO (1) WO2000044378A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1140071T1 (en) 1998-12-23 2007-08-31 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co Medicinal compositions for preventing or treating heart failure
US7076287B2 (en) * 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CN1662256A (en) * 2002-05-17 2005-08-31 诺瓦提斯公司 Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction
SE0302331D0 (en) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (en) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 Novel compounds with effects of reducing blood pressure and protecting cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (en) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-ii-receptorantagonist for the treatment and prophylaxis of coronary heart diseases
FR2716882B1 (en) * 1994-03-04 1996-04-05 Roussel Uclaf Use of imidazole derivatives for the treatment of conditions involving the AT1 and AT2 receptors of Angiotensin, some of these products, their preparation, pharmaceutical compositions.
DE4432860A1 (en) * 1994-09-15 1996-03-21 Merck Patent Gmbh imidazopyridines
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Similar Documents

Publication Publication Date Title
RU2006135205A (en) APPLICATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATMENT OF ACUTE MYOCARDIAL INFARCTION
RU2002129558A (en) A COMBINATION AT LEAST OF TWO COMPOUNDS SELECTED FROM AT AN ANTAGONISTIC GROUPS, ACE RECEPTOR OR ACE INHIBITORS (ANGIOTENZIN-CONVERSING ENZYME) OR HMG-β-RESOURSE-RESIDUAL RESIDUES
JP2004513920A5 (en)
JP2005041875A5 (en)
IL160643A (en) Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit
RU2006132668A (en) SYNERGETIC COMBINATIONS THAT CONTAIN A RENIN INHIBITOR, INTENDED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
RU2001122113A (en) The use of angiotensin II receptor antagonists for the treatment of acute myocardial infarction
US20090247582A1 (en) Methods of treating atherosclerosis
RU99112517A (en) ANTI-THROMBOSIS ORGANIC NITRATES
SK14642002A3 (en) Combination of at least two compounds selected from an AT1-receptor antagonist or an ACE inhibitor or a HMG-CoA reductase inhibitor groups
JP2004514703A (en) Organic compound combination
US20030171415A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
AU2001295465A1 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
US20120196850A1 (en) ASSOCIATION OF A SINUS NODE If CURRENT INHIBITOR AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
JP2002535367A5 (en)
WO1994028924A1 (en) Combination of angiotensin converting enzyme inhibitors and aii antagonists
US4962105A (en) Potentiation of antihypertensive effect of ace inhibitors
US20060154976A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
US20030158223A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
US20080114046A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
JPH1081633A (en) Medicinal composition
ZA200300556B (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors.
TH60578A (en) Derivatives 4- (2-phenylthiazole-5-il) -1,4-diasabicyclol [3.2.2] nonan, its preparation And its therapeutic uses
TH50482A3 (en) Concomitant treatment of enzyme inhibitors which convert angiotensin and aldosterones. Antagonists for reducing the incidence and mortality of cardiovascular disease.
RU2005127333A (en) MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA